Physician profile
Joss Cohen
NPI 1235689332
$7,644.00
in general payments reported to CMS, 2019-2025
23 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $359 · 2022: $726 · 2023: $1,674 · 2024: $2,284 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,260 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,260.19 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,420.75 | 2022-2025 | Zilbrysq, Rystiggo, Briviact |
| Abbvie INC. | $1,390.14 | 2022-2025 | Botox, Ubrelvy |
| Alexion Pharmaceuticals, INC. | $1,003.73 | 2021-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $688.39 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $685.70 | 2022-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $359.13 | 2021-2025 | Leqembi, Vumerity, Tysabri |
| Tg Therapeutics, INC. | $284.88 | 2024-2025 | |
| Lundbeck LLC | $279.10 | 2021-2025 | Vyepti |
| Pfizer INC. | $259.15 | 2023-2025 | |
| Emd Serono, INC. | $173.10 | 2023-2025 | Mavenclad, Mavenclad |
| Eisai INC. | $141.71 | 2024-2025 | |
| Amgen INC. | $141.52 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $136.74 | 2021-2023 | Austedo, Austedo Xr |
| Ipsen Biopharmaceuticals, INC | $129.86 | 2024-2025 | Dysport |
| Csl Behring | $123.79 | 2025 | Hizentra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $95.35 | 2023-2025 | Emgality, Reyvow, Kisunla |
| Impel Pharmaceuticals INC. | $80.20 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $72.81 | 2022 | |
| Allergan, INC. | $59.74 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $54.53 | 2024-2025 | Nuplazid |
| Genentech USA, INC. | $30.88 | 2024 | Ocrevus |
| Averitas Pharma INC. | $17.24 | 2023 | Qutenza |
| Axsome Therapeutics, INC. | $15.56 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joss Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.